You are here

Article Text

Article menu
Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Treatment of Stargardt disease with dobesilate
  1. Pedro Cuevas1,
  2. Luis A Outeiriño2,
  3. Javier Angulo1,
  4. Guillermo Giménez-Gallego3
  1. 1Departamento de Investigación, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain
  2. 2Departamento de Oftalmología, Hospital de Día Pío XII, Madrid, Spain
  3. 3Departamento de Estructura y Función de Proteínas, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain
  1. Correspondence to Professor Pedro Cuevas, pedro.cuevas{at}hrc.es

Summary

Stargardt disease is a common inherited macular degeneration characterised by a significant loss in the central vision during the first or second decade of the life. Bilateral atrophic changes in the central retina are associated with degeneration of photoreceptors and underlying retinal pigment epithelium, and yellow flecks are extending from the macula. We present a patient with Stargardt disease treated with an intravitreal injection of dobesilate, showing an improvement of visual acuity 4 weeks after treatment

https://doi.org/10.1136/bcr-2012-007128

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text